Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 249

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Checkpoint blocking antibodies in cancer immunotherapy

Open access
Kyi, Chrisann, Postow, Michael A.·2014·FEBS Letters

Abstract

Cancers can be recognized by the immune system, and the immune system may regulate and even eliminate tumors. The development of checkpoint blocking antibodies, such as those directed against cytotoxic T‐lymphocyte antigen 4 (CTLA‐4) and programmed death 1 receptor (PD‐1), have demonstrated significant recent promise in the treatment of an expanding list of malignancies. While both CTLA‐4 and PD‐1 function as negative regulators, each plays a non‐redundant role in modulating immune responses. CTLA‐4 attenuates the early activation of naïve and memory T cells. In contrast, PD‐1 is primarily involved in modulating T cell activity in peripheral tissues via interaction with its ligands, PD‐L1 and PD‐L2. Unfortunately, not all patients respond to these therapies, and evaluation of biomarkers associated with clinical outcomes is ongoing. This review will examine the efficacy, toxicities, and clinical development of checkpoint blocking antibodies, including agents already approved by the US Food and Drug Administration (anti‐CTLA‐4, ipilimumab) or in development (anti‐PD‐1, PD‐L1). Future studies will likely uncover new promising immunologic checkpoints to target alone or in combination with other immunotherapeutic approaches, chemotherapy, radiotherapy, and small molecules.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.febslet.2013.10.015

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 249

Metadata

Authors
Kyi, C., & Postow, M. A.
Venue
FEBS Letters
Publisher
Wiley
Published
2013-10-23
Volume
588
Issue
2
Pages
368-376
ISSN
  • 0014-5793 (ISSN-L)
  • 1873-3468
OpenAlex
W2069592230
Cited by
249
References
23
FWCI
15.97
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Checkpoint blocking antibodies in cancer immunotherapy. https://app.cochat.ai/papers/10.1016/j.febslet.2013.10.015
The paper
Kyi, C., & Postow, M. A. (2014). Checkpoint blocking antibodies in cancer immunotherapy. FEBS Letters. https://doi.org/10.1016/j.febslet.2013.10.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.